AVCN Avicanna

Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine

Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine

Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid Medicine

Live and Virtual Symposium on June 6th, 2025, at the MaRS Discovery District, Toronto 

TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it will host its 5th medical symposium on Cannabinoid-based Medicine – “From Emerging Evidence to Clinical Practice” from the MaRS Discovery District, Toronto, Friday June 6th, 2025.

The Symposium is open to healthcare practitioners and researchers and will include various speakers covering a variety of topics-ranging from emerging evidence to current clinical practices on the practical application of cannabinoid-based medicine. The speakers include Canadian and international key opinion leaders, clinicians, and scientists from leading academic, research, and clinical organizations.

Featured Speakers and Topics:

SpeakerTopic
Dr. Carrie Cuttler

Washington State University
Getting by Without the High: Examining the Therapeutic Potential of Cannabigerol
Dr. Jason McDougall

Dalhousie University
A Role for Cannabinoids in the Management of Arthritis
Carlo De Angelis

Sunnybrook Health Sciences Centre
Tales From the Front Lines: Unique Uses of Medical Cannabis – Patient Cases
Dr. Daniel Bear

Humber College
Building Better Drugs Education for People Who Know a Lot About (Certain) Drugs - Considerations for Medical Cannabis
Dr. Zachary Walsh

University of British Colombia
Cannabis and Problematic Substance Use: New Finding on Substitution and Harm Reduction from High-Risk Populations
Dr. Kelly Dunn

John Hopkins School of Medicine
Human Laboratory Evidence of Opioid-cannabinoid Interactions and the Role of Opioids
Dr. Hance Clarke

University Health Network
Canadian Medical Cannabis Clinical Trials Network
Dr. Jennifer Baumbusch

University of British Columbia
Cannabis Use among Older Adults: Current Research and Implications for Clinical Practice
Dr. Evan Lewis

North Toronto Neurology
Cannabis-Based Therapies for Epilepsy: What’s New & What’s Next



“Building on the success of last year's event, this year's Symposium seeks to enhance our collective understanding of cannabinoid-based medicines arising from the latest developments on an international perspective. We are pleased to host this symposium and provide a platform for these important exchanges, fostering collaboration and education of the medical community on medical cannabis” stated Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna.

In addition to keynote presentations and panel discussions, Avicanna invites abstract submissions for a dedicated poster presentation session. Researchers, clinicians and health care practitioners are encouraged to submit abstracts showcasing their latest findings and developments in the field of cannabinoid-based medicine. This poster session will serve as a valuable platform for knowledge exchange and will foster meaningful dialogue among attendees.

To register for the symposium and submit abstract for poster presentation: 

Health care practitioners and researchers, may apply for registration and submit abstracts for poster presentation at:

About Avicanna:

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

  • Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
  • Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
  • Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
  • Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc

Stay Connected 

For more information about Avicanna, visit  or contact Ivana Maric by email at . 

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.



EN
07/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avicanna

 PRESS RELEASE

Avicanna Announces Revocation of Management Cease Trade Order

Avicanna Announces Revocation of Management Cease Trade Order TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the Management Cease Trade Order (“MCTO”) issued on April 4, 2025 by the Ontario Securities Commission (“OSC”) has now been revoked. As previously announced, all required filings have been filed by the Company. Following the filing of required fili...

 PRESS RELEASE

Avicanna Reports Full Year 2024 Audited Financial Statement

Avicanna Reports Full Year 2024 Audited Financial Statement 2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its full year 2024 results, audited financial statements with management’s discussion and analysis have bee...

 PRESS RELEASE

Avicanna Announces Receipt of Management Cease Trade Order and Provide...

Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 1 week TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, that further to its March 31, 2025 new release, its application for a management cease trade order (“MCTO”) under National Pol...

 PRESS RELEASE

Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medi...

Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid MedicineLive and Virtual Symposium on June 6th, 2025, at the MaRS Discovery District, Toronto  TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it will host its 5th medical symposium on Cannab...

 PRESS RELEASE

Avicanna Announces Late Filing of Financial Statements and Application...

Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 2 weeks TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces that it will miss the deadline of March 31, 2025 (“Filing Deadline”) to file the Company’s audited consol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch